ANALYSIS OF THE USE OF DRUG CATEGORY OFF LABEL IN HOSPITAL PATIENTS AT HOSPITAL

Rusli rusli, Junaedi Junaedi, Hubbi HP, Agust Dwi Djajanti, Jefrin Sambara, Nielma Aulia, Herman Herman

Abstract


The increasing use of off-label category drugs is the reason clinicians use these drugs because the clinical response has not had a significant impact on treatment as well as various reasons for specific therapeutic purposes. While adverse events and adverse reactions to drugs from off-label category drugs tend to continue to increase, so we need continuous and continuous data and study of therapies about the use of off-label category drugs. The purpose of this study was to analyze the characteristics of usage patterns and reasons for administering off-label categories of drugs to inpatients in hospitals. This research was conducted at the hospital. Dr. Wahidin Sudiro Husodo Makassar. Research uses data in the form of inpatient prescriptions in the internal medicine, children's and obgin's sections with a prescription number of 150 sheets. The results showed that the indication of disease using off-label category drugs was not dominated by one particular disease but rather based on the needs and conditions of the disease and the drug availability of the off label drug. The pattern of treatment using off-label categories of drugs given orally is the most dominant given by the clinician. The type of drug that is commonly used in the off-label category is not dominated by certain classifications, but drugs with indicated anti-pain are the choices for the type of drug used. The reason the clinician decides to use off-label category drugs is because the on-label category drugs have not been able to contribute to healing the diagnosis of the disease while some drugs based on experience for drugs that have not been approved can provide a significant healing process.

 

Keywords; off-label category drug analysis


Full Text:

PDF (Full Text)

References


Adriana, C. S. G., Adriano, M.M.R., Ana C.G.M., Maria, C.F.B., 2017, Use of Unlicensed and Off-Label Drugs in Neonates in a Brazilian University Hospital, Brazilia Journal Pharmaceutical Science, 2017;53(3): e00252 Page, 1-10

Alyssa M Peckham, Kirk E Evoy, Leslie Ochs, Jordan R Covvey, 2018, Gabapentin for Off-Label Use: Evidence-Based or Cause for Concern, PMC 2018; 12: Published online 2018 Sep 23. doi: 10.1177/1178221818801311

Badan POM RI, 2012, Pedoman Monitoring Efek Samping Obat (MESO) Bagi Tenaga Kesehatan, Direktorat Pengawasan Distribusi Produk Terapetik dan PKRT Jakarta, hal. 4-6.

Bavdekar, S.B., Gogtay, N.J., 2005, Unlicensed and Off-Label Drug Use in Children, Journal of Postgraduate Medicine, December 2005, Vol. 51, Issue 4, p. 249-252

Bellis, J.R., Kirkham, J.J., Nunn, A.J., Pirmohamed, M.,2013, Adverse Drug Reactions and Off-Label and Unlicensed Medicines in Children: A Prospective Cohort Study of Unplanned Admissions to A Paediatric Hospital, British Journal of Clinical Pharmacology, 77:3, 545–553

Blenkinsopp, A., Bradley, C., 1996, Patients, society, and the increase in self medication, BMJ Volume 312, 9 March 1996, 629-632

Catherine M.Zip MD, 2010, Innovative Use of Topical Metronidazole, Volume 28, Issue 3, July 2010, Pages 525-534

Cuzzolin, L., 2014, Off-Label Drug in the Newborn, Department of Public Health and Community Medicine – Section of Pharmacology, University of Verona, Italy

doi: 10.7363/030224

Direktorat Jenderal Bina Kefarmasian dan Alat Kesehatan Departemen Kesehatan Republik Indonesia, 2011, Modul Penggunaan Obat Rasional, Jakarta, 1, 69, 97, 137.

Hilman Zulkifli Amin, Irsan Hasan, 2015, Penyekat Beta sebagai Terapi Anti-Remodeling, eJKI, Vol. 3, No. 1, April 2015

Journal of Pediatric and Neonatal Individualized Medicine 2014;3(2):e030224

Morgan E.K.T, Williamson M, 2009, Medication Safety in the Community: A Review of the Literature, National Prescribing Service. Sydney, 10-12.

Purba, A.V., 2007, Penggunaan Obat Off-Label Pada Pasien Anak, Puslitbang Sistem dan Kebijakan Kesehatan Badan Litbangkes, Buletin Penelitian Kesehatan, Vol. 35, No. 2, 2007:90 – 97

Refik Demirtunc, Gul Babacan Abanonu, Hilal Guner Upcin, 2009, Effectiveness of Insulin Aspart On The Treatment Of Hyperkalemia In Patients With Diabetic Renal Failure, European Journal of Internal Medicine, Volume 20, Supplement 1, May 2009, Page S204

Stafford, R.S., 2008, Regulating Off-Label Drug Use, Rethinking the Role of the FDA, April 3, 2008, The New England Journal Medicine, 2008; 358:1427-1429

Suharjono, 2009, Obat Kategori Off-Label dalam Aplikasi Klinik

Turner, J.R, 2009, Drug safety, medication safety, patient safety : an overview of recent FDA guidances and initiatives, Campbell University School of Pharmacy, North Carolina, US, and Visiting Fellow, Center for Medicine in the Public Interest, New York, US (rturner@cmpi.org) Regulatory Rapporteur – Vol 6, No 4, April 2009, 1-8.

Yu, K.H, Nation, R.L, Dooley, M.J, 2005, Multiplicity of medication safety terms, definitions and functional meanings: when is enough enough?, Quality Safety Health Care; 14, 358–363.

World Health Organization, 1987, The Rational Use of Drugs, Geneva, 17, 138.




DOI: https://doi.org/10.32382/uh.v2i1.1233

Refbacks

  • There are currently no refbacks.